Top Growth Trends in the Oral Biologics & Biosimilar Drugs Market: Key Insights and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Does the Projected Growth of the Oral Biologics & Biosimilar Drugs Market Compare Over the Forecast Period?
In recent times, there has been a swift expansion in the market size of oral biologics & biosimilar drugs. The market is predicted to increase from $7.19 billion in 2024 to $8.6 billion in 2025, growing at a compound annual growth rate (CAGR) of 19.6%. The noteworthy growth observed in the historical period is due to factors such as the increasing occurrence of chronic illnesses, enhanced understanding of oral biologics, growing number of patent expirations, and heightened demand for biosimilars.
In the coming years, the oral biologics & biosimilar drugs market is projected to experience fast-paced expansion. The market is forecasted to reach $15.11 billion by 2029, growing at a compound annual growth rate (CAGR) of 15.1%. The market expansion during the forecast period might be attributed to factors such as targeted therapy, a heightened emphasis on preventive medicine, an increase in healthcare expenditure, and an aging population. Notable trends during this period are expected to include progress in oral delivery technology, the introduction of orally administered biologics, innovation in biosimilars, and a focus on patient-centered care.
Which Factors Are Enhancing the Growth of the Oral Biologics & Biosimilar Drugs Market?
The escalating incidence of long-term illnesses like arthritis, asthma, and cancer is anticipated to significantly propel the oral biologics and biosimilar market. Extended work hours, minimal physical exercise, along with poor eating and drinking practices add to the commonality of these chronic illnesses. Biologics are becoming more commonly utilized in their treatment as they stimulate the immune response against cancer cells and help to clear them from the body. For example, a United Nations article in May 2023 forecasts that by 2030, chronic illnesses will account for 70% of global deaths. The worldwide impact of chronic disease is predicted to reach about 60%. Consequently, the escalating incidence of these long-term illnesses is expected to boost the demand for biologics and biosimilar medicines, thereby fostering the growth of the oral biologics & biosimilar drugs market.
Explore Comprehensive Insights Into The Global Oral Biologics & Biosimilar Drugs Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp
Who Are the Key Players Steering the Development of the Oral Biologics & Biosimilar Drugs Market?
Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.
How Are Market Trends and Shifts Impacting the Growth Trajectory of the Oral Biologics & Biosimilar Drugs Market?
The oral biologics and biosimilar market is currently seeing a surge in the development of novel insulin biosimilars. Market leaders in the field of oral biologics and biosimilars are channeling resources towards the production of an insulin biosimilar replacement. This has stirred a competitive environment among different biosimilar manufacturers. An exemplification of this trend is when, in April 2023, Eli Lilly and Company, a US firm that produces oral biologics and biosimilar medicines, introduced a new insulin glargine biosimilar called Rezvoglar (insulin glargine-aglr). Insulin glargine products such as these are utilized to better regulate blood sugar levels in adults, children, and infants with type 1 diabetes and adults with type 2 diabetes.
Secure Your Global Oral Biologics & Biosimilar Drugs Market Report Now for Fast and Efficient Delivery!
Which Primary Segments of the Oral Biologics & Biosimilar Drugs Market Are Driving Growth and Industry Transformations?
The oral biologics & biosimilar drugs market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab
Which Geographical Regions Are Shaping the Oral Biologics & Biosimilar Drugs Market Growth?
The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
How Do Experts Define the Scope of the Oral Biologics & Biosimilar Drugs Market?
A biosimilar refers to a medication that closely resembles a biological medication in both structure and function. A biological drug, however, is a treatment created using a biological system, such as yeast, bacteria, or animal cells. A biological product is considered ‘biosimilar’ if it is extremely similar to and bears no discernible clinical differences from an FDA-approved reference product already in use.
Browse Through More Similar Reports By The Business Research Company:
Dental Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dental-services-global-market-report
Dental Equipment And Supplies Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dental-equipment-and-supplies-global-market-report
Dental Practice Management Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dental-practice-management-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
